Incyte (INCY) shares soared 5.5% in the last trading session to close at $102.69. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the ...
Incyte (INCY) has been quietly outperforming the broader biotech space this year, with the stock up about 46% over the past year and more than 40% year to date, drawing fresh attention. See our latest ...
Hosted on MSN
Mizuho upgrades Incyte (INCY)
Fintel reports that on December 8, 2025, Mizuho upgraded their outlook for Incyte (NasdaqGS:INCY) from Neutral to Outperform. Analyst Price Forecast Suggests 6.11% Downside As of December 6, 2025, the ...
Barclays analyst Etzer Darout maintained a Buy rating on Incyte today and set a price target of $115.00. Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest ...
Incyte’s Jakafi LOE overhang masked a quietly transforming, profitable biotech whose non‑Jakafi portfolio is now compounding fast enough to support a structural rerating, despite 2028 risks. Q3 2025 ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...
We recently published Wall Street Can’t Keep up With These 10 Crushing Stocks; 6 at Fresh Record Highs. Incyte Corp. (NASDAQ:INCY) is one of the best-performing on Monday. Incyte extended its winning ...
Incyte Corporation (NASDAQ:INCY) ranks among the best biotech stocks to buy. RBC Capital retained its Sector Perform rating on Incyte Corporation (NASDAQ:INCY) and increased its price target from $72 ...
Incyte's recent earnings call disappointed the market, causing a 10.52% drop, but management's bullish comments and no debt position suggest a promising future. Technically, INCY is currently below ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback